38 related articles for article (PubMed ID: 38688588)
1. Nivolumab-induced SJS/TEN-like reaction.
Fazelpour S; Gibson F; Caligayahan M; Vashi N
Arch Dermatol Res; 2024 May; 316(6):264. PubMed ID: 38795166
[No Abstract] [Full Text] [Related]
2. Systematic review and meta-analysis efficacy and safety of immune checkpoint inhibitors in advanced melanoma patients with anti-PD-1 progression: a systematic review and meta-analysis.
Alrabadi NN; Abushukair HM; Ababneh OE; Syaj SS; Al-Horani SS; Qarqash AA; Darabseh OA; Al-Sous MM; Al-Aomar SR; Ahmed YB; Haddad R; Al Qarqaz FA
Clin Transl Oncol; 2021 Sep; 23(9):1885-1904. PubMed ID: 33877531
[TBL] [Abstract][Full Text] [Related]
3. Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma.
Gambichler T; Seifert C; Lehmann M; Lukas C; Scheel C; Susok L
Immunotherapy; 2020 May; 12(7):439-444. PubMed ID: 32308086
[No Abstract] [Full Text] [Related]
4. Nivolumab-induced systemic lymphadenopathy occurring during treatment of malignant melanoma: a case report.
Kubo T; Hino A; Fukushima K; Shimomura Y; Kurashige M; Kusakabe S; Nagate Y; Fujita J; Yokota T; Kato H; Shibayama H; Tanemura A; Hosen N
Int J Hematol; 2022 Aug; 116(2):302-306. PubMed ID: 35201591
[TBL] [Abstract][Full Text] [Related]
5. Systemic Scleroderma Induced by Nivolumab in Malignant Melanoma.
Loupret T; Boisseau R; Lopez JG; Bertin P; Vergne-Salle P
In Vivo; 2024; 38(3):1451-1453. PubMed ID: 38688588
[TBL] [Abstract][Full Text] [Related]
6. Dermatomyositis in a patient undergoing nivolumab therapy for metastatic melanoma: a case report and review of the literature.
Kosche C; Stout M; Sosman J; Lukas RV; Choi JN
Melanoma Res; 2020 Jun; 30(3):313-316. PubMed ID: 31567590
[TBL] [Abstract][Full Text] [Related]
7. Dermatomyositis associated with nivolumab therapy for melanoma: a case report and review of the literature.
Messer A; Drozd B; Glitza IC; Lu H; Patel AB
Dermatol Online J; 2020 Aug; 26(8):. PubMed ID: 32941716
[TBL] [Abstract][Full Text] [Related]
8. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
9. An update on the safety of nivolumab for the treatment of advanced melanoma.
Czarnecka AM; Rutkowski P
Expert Opin Drug Saf; 2020 Apr; 19(4):409-421. PubMed ID: 32293935
[No Abstract] [Full Text] [Related]
10. Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls.
Darnell EP; Mooradian MJ; Baruch EN; Yilmaz M; Reynolds KL
Curr Oncol Rep; 2020 Mar; 22(4):39. PubMed ID: 32200442
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
